Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978171093> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2978171093 endingPage "S538" @default.
- W2978171093 startingPage "S537" @default.
- W2978171093 abstract "Introduction: Serious adverse events (SAEs) are associated with many gastrointestinal (GI) drugs. Based on extensive safety data, patients treated with alosetron may experience a low incidence of two SAEs (ischemic colitis [IC] and complications of constipation [CoC]). However, SAEs associated with alosetron are perceived as being more frequent and serious than SAEs with other drugs used to treat chronic GI conditions. This analysis compares SAE risks associated with alosetron vs. other GI drugs. Methods: Systematic literature searches using online databases were performed to identify controlled randomized studies, retrospective studies, meta-analyses, postmarketing prospective studies, and population-based cohort studies on GI drugs used to treat chronic conditions that also included documented SAE(s) data. These safety results were compared with retrospective analyses of health claims data for alosetron SAEs of IC and CoC. Results: The table lists GI drug-associated SAE(s) and risk(s). Conclusion: Commonly used GI drugs such as metronidazole, metoclopramide, infliximab, mesalamine, and PPIs are associated with significant SAEs. Risks for these SAEs appear to be comparable to or greater than the risks of IC and CoC with alosetron. Therefore, a comprehensive assessment by prescribers of patient risk tolerance and drug safety risk, balanced against potential drug benefit, is warranted during selection of effective pharmacotherapeutic options for GI disorders. Disclosure - Dr. Lucak: Consultant for Prometheus Laboratories Inc. Dr. Nicandro: Employee of Prometheus Laboratories Inc. Dr. Earnest: Consultant for Prometheus Laboratories Inc.Table 1" @default.
- W2978171093 created "2019-10-10" @default.
- W2978171093 creator A5029797738 @default.
- W2978171093 creator A5060981692 @default.
- W2978171093 creator A5077632073 @default.
- W2978171093 date "2014-10-01" @default.
- W2978171093 modified "2023-09-26" @default.
- W2978171093 title "Risk of Serious Adverse Events With Alosetron is Similar to or Less Than That Associated With Other Drugs Prescribed for Chronic GI Disorders" @default.
- W2978171093 doi "https://doi.org/10.14309/00000434-201410002-01817" @default.
- W2978171093 hasPublicationYear "2014" @default.
- W2978171093 type Work @default.
- W2978171093 sameAs 2978171093 @default.
- W2978171093 citedByCount "0" @default.
- W2978171093 crossrefType "journal-article" @default.
- W2978171093 hasAuthorship W2978171093A5029797738 @default.
- W2978171093 hasAuthorship W2978171093A5060981692 @default.
- W2978171093 hasAuthorship W2978171093A5077632073 @default.
- W2978171093 hasConcept C120665830 @default.
- W2978171093 hasConcept C121332964 @default.
- W2978171093 hasConcept C126322002 @default.
- W2978171093 hasConcept C167135981 @default.
- W2978171093 hasConcept C177713679 @default.
- W2978171093 hasConcept C197636746 @default.
- W2978171093 hasConcept C197934379 @default.
- W2978171093 hasConcept C2777138892 @default.
- W2978171093 hasConcept C2779134260 @default.
- W2978171093 hasConcept C2781112942 @default.
- W2978171093 hasConcept C2908647359 @default.
- W2978171093 hasConcept C61511704 @default.
- W2978171093 hasConcept C71924100 @default.
- W2978171093 hasConcept C99454951 @default.
- W2978171093 hasConceptScore W2978171093C120665830 @default.
- W2978171093 hasConceptScore W2978171093C121332964 @default.
- W2978171093 hasConceptScore W2978171093C126322002 @default.
- W2978171093 hasConceptScore W2978171093C167135981 @default.
- W2978171093 hasConceptScore W2978171093C177713679 @default.
- W2978171093 hasConceptScore W2978171093C197636746 @default.
- W2978171093 hasConceptScore W2978171093C197934379 @default.
- W2978171093 hasConceptScore W2978171093C2777138892 @default.
- W2978171093 hasConceptScore W2978171093C2779134260 @default.
- W2978171093 hasConceptScore W2978171093C2781112942 @default.
- W2978171093 hasConceptScore W2978171093C2908647359 @default.
- W2978171093 hasConceptScore W2978171093C61511704 @default.
- W2978171093 hasConceptScore W2978171093C71924100 @default.
- W2978171093 hasConceptScore W2978171093C99454951 @default.
- W2978171093 hasLocation W29781710931 @default.
- W2978171093 hasOpenAccess W2978171093 @default.
- W2978171093 hasPrimaryLocation W29781710931 @default.
- W2978171093 hasRelatedWork W1973741006 @default.
- W2978171093 hasRelatedWork W2007332402 @default.
- W2978171093 hasRelatedWork W2056967779 @default.
- W2978171093 hasRelatedWork W2066797670 @default.
- W2978171093 hasRelatedWork W2273630113 @default.
- W2978171093 hasRelatedWork W2740091946 @default.
- W2978171093 hasRelatedWork W3023542470 @default.
- W2978171093 hasRelatedWork W3041627819 @default.
- W2978171093 hasRelatedWork W3154734119 @default.
- W2978171093 hasRelatedWork W2073770480 @default.
- W2978171093 hasVolume "109" @default.
- W2978171093 isParatext "false" @default.
- W2978171093 isRetracted "false" @default.
- W2978171093 magId "2978171093" @default.
- W2978171093 workType "article" @default.